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Abstract
Introduction. The purpose of the study was to assess the effectiveness of endovascular mechanochemical 
ablation of the Great Saphenous vein and the Small Saphenous vein (GSV/SSV) using the use of Flebogrif® 
catheter and method, based on results obtained from the analysis of 200 patients.
Material and methods. 200 patients underwent mechanochemical ablation using the Flebogrif® technique, 
of the 200 patients, 172 patients experienced insufficiency of the GSV and 28 experienced insufficiencies of 
the SSV. Follow-up assessment was established by outpatient appointments at 1, 3, 6, and 12 months postop-
eratively. During each subsequent visit, the result of the procedure was evaluated with the use of ultrasound. 
Furthermore, the intensity of clinical manifestations was assessed with the use of VCSS, CEAP, VASP scales. Any 
complications were also noted.
Results. During 12-month follow-up the number of participants decreased to 168 (152 female, 16 male). 
Complete closure of the vein was achieved in 154 patients (140 female, 14 male). According to adopted 
criteria, 15 cases of recanalization were detected (10 complete and 5 partial). Based on the obtained results 
the effectiveness of the method was assessed at 92%.
Conclusions. The statistical analysis of the 12-month follow-up data allowed us to conclude the following the 
procedural method had 92% of effectiveness at 12-month follow-up, vein diameter was not a significant limitation 
for the application of the technique, there was a low rate of serious complications, and adverse cosmetic effect 
was minimal. However , the method requires further long-term follow-up to allow for a complete assessment.
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Introduction
The significant number of patients presenting with 
chronic venous insufficiency remains an inspiration for 
further search of an effective therapeutic method asso-
ciated with long-lasting effectiveness, high level of safety, 
and broad accessibility [1, 2]. Endovascular thermal ab-
lation techniques introduced in the early 1990s utterly 
transformed vein surgery, resulting in a new minimally 
invasive approach [3]. The procedures gained the ap-
proval of both patients and physicians [4]. Due to their 
high efficacy and reproducibility of the outcome, they 
remain the most commonly used procedures for endo-
vascular GSV/SSV ablation [4]. Our proposed method of 
endovascular mechanochemical GSV/SSV ablation with 
the use of Flebogrif® catheter is an effective, minimally 
invasive treatment of venous insufficiency [5]. The model 
pathological mechanism of Flebogrif® method is based 
on shrinking of the veins, and the resultant fibrosis due to 
the inflammatory process as a consequence of chemical 
damage to the endothelium initialized by mechanical 
injury of the vessel wall.
The main goal of this study was to assess: the ef-
fectiveness of mechanochemical ablation of the GSV/ 
/SSV using the Flebogrif catheter (expressed as the 
percentage of fully closed veins). Clinical effectiveness 
based on the evaluation of the intensity of clinical signs 
at fixed follow-up intervals, using the VCSS, CEAP, 
VAPS scales, and safety of the procedure, based on the 
analysis of the type and clinical significance of observed 
complications were also assessed. 
Material and methods
200 patients underwent surgical procedures from 
January 2013 to December 2015 due to Great Sa-
phenous Vein (GSV) and Small Saphenous Vein (SSV) 
insufficiency. Tables 1 and 2 present the demographic 
data the respective number of participants during the 
12 month follow-up period. 
The study was performed after obtaining approval 
from the Ethics Committee at the Medical University 
of Lublin. The analyzed patients met all the inclusion 
criteria, and no exclusion criteria were established. 
After signing the consent form, each patient underwent 
an ultrasound to confirm the insufficiency of the GSV/ 
/SSV. Special attention was given to such deep vein 
pathologies, such as post-thrombotic changes, partial 
obstruction, and total occlusion. The ultrasound was 
completed while in a standing position. Ascertaining the 
length of the insufficient vein helped to better deter-
mine the proper site for the puncture of the vessel. In 
the case of the GSV the optimal puncture site location 
was the lowest point in the segment of the insufficient 
vein, whereas the SSV was punctured maximally pe-
ripherally in relation to sapheno-popliteal junction. 
Table 3 shows the diameter, number and location of 
the operated veins.
During the preoperative assessment (baseline), the 
intensity of clinical signs reflecting illness severity was 
collected and analyzed. The procedures were per-
formed in a conventionally equipped operating room. 
In cases of GSV insufficiency, the patient was placed 
in a supine position, whereas in SSV cases, in a prone 
position was preferred. The procedure was performed 
with a prepared set, consisting of 18G needle, 0,035 “J 
angulated wire”, 6 Fr vascular sheath, 2 syringes with 
a connector and a 6 Fr Flebogrif® catheter. Before 
use, all the equipment was flushed with saline. Under 
ultrasound guidance, the vein was punctured with 18G 
needle at the level determined preoperatively. The in-
troducer was inserted through venous cannula and its 
Table 1. Demographic data of the investigated group of patients
Gender Number of patients Age Total number of patients 
Max Average Minimum
Females 170 87 56 18
200
Males 30 75 46 23
Table 2. Number of patients over 12 months of observation
                   Postoperative 
                          time
Patients
Baseline day „0” 1 month 3 month 6 month 12 month
Number 200 198 182 179 174
Females 170 170 158 157 156
Males 30 28 24 22 18
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tip was advanced to the level of the Sapheno-Femoral 
junction in GSV cases and the Sapheno-Popliteal junc-
tion in SSV cases. Before inserting the vascular sheath, 
the skin was anaesthetized with 1ml of 1% Lignocaine. 
A small skin incision at the puncture site facilitated its 
introduction. The Flebogrif® catheter was inserted on 
the introducer through the vascular sheath, and its tip 
was positioned 2 cm from Sapheno-Femoral junction. 
Maintaining this distance prevented the application of 
obliterating agent into the femoral vein. Proper position 
of the Flebogrif ® was confirmed by ultrasound (Fig. 1). 
By retracting the outer sheath, five cutting elements 
were released. The hooked tips of these elements “bit” 
into the venous wall. A crucial aspect of the procedure 
was to withdraw the Flebogrif ® catheter at a constant 
speed of 5 cm/s with simultaneous injection of a frothed 
obliterating agent, 3% Polidocanol, which was prepared 
according to the Tessari method (1 ml of sclerosing 
agent mixed with 4 ml of air). To maintain its proper 
consistency, the obliterating substance was prepared 
directly before its application. The construction of 
the catheter and functions of its constituent parts are 
presented in Figure 2. 
The volume of 3% of foam applied did not exceed 
10 ml (1 ampule/60 mg of pure Polidocanol frothed 
according to Tessari method in 1:4 ratio). Small varices 
were closed at the same time with 1% foam. How-
ever, the entire (main vein trunk + varices) amount 
of obliterating agent did not exceed 1 mg/kg. Larger 
varicose veins requiring a larger volume of sclerosant 
were obliterated in the next session. The estimated 
volume of foamed substance administered to the vein 
lumen was 1 ml per 5 cm of vein. The maximum amount 
of Palidocanol used was 10 ml, and the minimum was 
4 ml. Postoperatively, every patient was fitted with 
a compression stocking with a pressure of 20–30 mm Hg. 
The patient was advised to use the compression 
stocking continuously for 24 hrs after the procedure 
as well as during the daytime for 4 weeks following the 
intervention. Each patient returned to normal physical 
activity immediately after the procedure and was dis-
charged home within the following hour. Follow-up 
appointments were planned for 1, 3, 6, 12, 24, and 36 
months postoperatively.
Obtained data analysis
During arranged follow-up visits, evaluation of each 
patient clinical condition was performed with the use of 
the VCSS, CEAP scales, in combination with the visual 
analogue pain scale. Obtained data from the VCSS, 
CEAP and VAP scale underwent statistical analysis 
using the Friedman ANOVA test. Regarding the VCSS 
scale, a statistically significant decrease in clinical signs 
was observed in comparison to day “0” (baseline) 
(p < 0,001). No statistically significant differences were 
observed between the evaluation at 6 and 12 months. 
Table 4 presents the statistical characteristics of the 
obtained data. 
Table 3. Diameter, number, and the side of puncture of operated veins
The diameter of the vein (from–to/average) Number of operated limbs Proportion
Below SFJ Mid-thigh Knee level Females Males GSV SSV
Right Left Right Left
4,2 3,8–17,1/6,2 3,8–11,9/6,6 68 102 13 17 172 (86%) 28 (14%)
Figure 1. The ultrasound view of working part of the Flebo-
grif®
Figure 2. A – working part (cutting elements) — of the 
Flebogrif® is advanced forward; B — Working part (cutting 
elements) withdrawn into the catheter. The black ring at the 
proximal end of the catheter (see the black arrow in the Figu-
re) indicates the position of the working part.
A
B
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Similarly, data from the evaluation of clinical state 
with the CEAP scale was statistically analyzed. A sta-
tistically significant decrease in clinical sign intensity 
was observed at follow-up points in relation to point 
“0” (baseline) (p < 0.001). No statistically significant 
differences were found between 6th and 12th month 
follow-up. Table 5 shows the statistical analysis of the 
CEAP scale. 
Data obtained from the visual analogue pain scale 
show a statistically significant drop at follow-up time 
points in comparison to the initial point “0”, with a 
significance level of p < 0.001. The difference between 
6th and 12th month follow-up points was not statistically 
significant (Table 6, Fig. 5.) 
The impact of the diameter of the closed vein with 
the Flebogrif® catheter was also analyzed. The type 
of recanalization is not differentiated statistically sig-
nificantly age, diameter, Sapheno-Femoral junction as 
well as the diameter of the trunk of Great Saphenous 
Vein, volume of the foam, and the length of the vein. 
Correlations were evaluated using rang Spearman table 
(Tables 6, 7).
Table 4. Statistical analysis for the assessment using the VCSS scale
n Min Max M SD Me p
VCSS — B 200 3.00 21.00 10.72 3.96 9.00
< 0.001
VCSS — 1 182 2.00 19.00 8.08 3.88 7.00
VCSS — 3 179 1.00 16.00 5.79 3.52 5.00
VCSS — 6 174 0.00 15.00 4.75 3.13 4.00
VCSS — 12 168 0.00 15.00 4.40 2.94 4.00
n: number; min: minimum; max: maximum; M: mean; SD: standard deviation; Me: median
Table 5. Statistical analysis for the assessment using the CEAP scale
n min max M SD Me p
CEAP — b 200 2.00 14.00 7.62 2.71 7.00
< 0.001
CEAP — 1 182 1.00 12.00 5.48 2.54 5.00
CEAP — 3 179 0.00 10.00 3.70 2.28 3.00
CEAP — 6 174 0.00 10.00 3.20 2.13 3.00
CEAP — 12 168 0.00 10.00 2.99 2.05 3.00
n: number; min: minimum; max: maximum; M: mean; SD: standard deviation; Me: median
Table 6. Statistical analysis for the assessment of using the VAPS scale within 12 months follow-up
n min max M SD Me p
VAPS — b 200 0.00 8.00 3.23 1.75 3.00
< 0.001
VAPS — 1 182 0.00 7.00 1.88 1.43 1.00
VAPS — 3 179 0.00 6.00 0.92 1.22 1.00
VAPS — 6 174 0.00 6.00 0.72 1.06 0.00
VAPS —12 167 0.00 4.00 0.60 0.86 0.00
n: number; min: minimum; max: maximum; M: mean; SD: standard deviation; Me: median
Table 7. The correlations between the diameter, length of the vein, the amount of foam and the full recanalization in the rang 
Spearman table
Feature Diameter SFJ Diameter GSV V foam L vein
Diameter SFJ – 0.6608 0.4200 –0.0389
Diameter GSV 0.6608 0.8002 –0.0548
V foam 0.4200 0.8002 0.2643
L vein –0.0389 –0.0548 0.2643 –
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During the follow-up period, 15 cases of recanaliza-
tion were observed. According to the European Con-
sensus for Sclerotherapy, the following criteria were 
adopted for complete recanalization: no change in the 
ablated vein’s diameter, full patency of the vessel, reflux 
over 0.5 s. Whereas partial recanalization was defined 
as a reduction in vein diameter, and reflux below 0.5 s. 
The analysis of observed cases enabled classification 
of 10 cases as complete recanalization and 5 as partial 
recanalization. Table 7 shows the distribution of re-
canalized veins. Based on 12-month follow-up analysis, 
method efficacy was evaluated to be at 92%.
Discussion
The method of endovascular ablation using the 
Flebogrif® catheter is another effective way of solving 
Table 8. The correlations between the diameter, length of the vein, the amount of foam and the full occlusion in the rang Spear-
man table
Feature Diameter SFJ Diameter GSV V foam L vein
Diameter SFJ 0.7800 0.3126 0.0823
Diameter GSV 0.7800 0.3011 0.0428
V foam 0.3126 0.3011 0.8366
L vein 0.0823 0.0428 0.8366
Figure 3. The time after surgery and VCSS values
Figure 4. Postoperative time and the values of CEAP scale
Figure 5. The time after surgery and values VAPS scale within 
12 months follow-up
Table 9. The cases of recanalized veins in relation to diameter of the vein, puncture site and amount of given foam
      Feature 
Gender
Recanalization 
GSV
Recanalization 
SSV
V. Diameter Puncture site Volume of  
sclerosing agent (ml)
L R L R Form — to (mm) Average Above Knee Belove GSV SSV
Females 7 1 4 – 5.8–20.1 13.1 2 4 7 4–8 2–5
Male 2 1 – – 6.8–10.0 11.4 0 0 2 5–8 –
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the problem of chronic vein insufficiency [6]. During 
the last quarter of a century, several new methods 
(EVLT, RFA, among others) were introduced. These 
procedures effectively drew the attention of both the 
medical community and patients as an endovascular, 
minimally-invasive way of treating superficial venous 
drainage insufficiency (GSV/SSV) [4, 6–8]. This pro-
cedure became a valuable alternative to the classical 
Babcock method of vein stripping, combined with mi-
ni-phlebectomy, which has been the dominating method 
in the treatment of various until the end of the 1980’s. 
In establishing the necessity of procedures we adopt the 
following criteria low cost, and thus better accessibility; 
short hospitalization with the possibility of outpatient 
intervention; and most importantly, safety as well as 
the permanence of therapeutic effect [2]. Certainly, 
both thermal methods and the recently introduced 
superheat approach fulfil these requirements [9]. Their 
undoubted advantage is short patient recovery time, 
very good cosmetic effect and, a relatively low number 
of complications, therefore results in a high quality of 
life index [10]. They are, however, a source of new 
types of complications such as neuralgia, hematomas, 
thermal injury of the skin. Additionally, this method 
requires tumescence which further complicates and 
prolongs the procedure [6]. At present, procedures 
with the use of a thermal factor (EVLR, RFA, STEAM) 
remain the most commonly performed procedures in 
cases of superficial venous trunk insufficiency [2, 3]. 
Another minimally-invasive procedure is foam oblit-
eration, either through a catheter or with direct vein 
puncture under ultrasound guidance [8, 11]. Although 
effectiveness assessed in randomized control trials is 
lower when compared to surgical treatment, its low lev-
el of invasiveness combined with low complication rate 
encourage its supporters to apply it in treatment [12]. 
The introduction of Flebogrif® to the European market 
opened a new chapter in the history of minimally-in-
vasive procedures, especially since the procedure 
completely eliminates the need for tumescence ma-
noeuvre as well as anaesthesia during the procedure 
[5, 13, 14]. At this point, it should be emphasized that 
Clarivein was historically the first procedure creating 
the mechanochemical group of procedures, which ef-
fectiveness and safety were confirmed in several studies 
[15–18]. Overall patients tolerated all the steps of the 
Flebogrif® procedure very well, and self-assessment of 
pain perception using a visual analogue scale allows as 
to generalize that the procedure is not painful. Another 
additional advantage of this method is quick return to 
the previous physical activity. In practice, patients who 
undergo the procedure Flebogrif® are able to walk 
directly afterwards and are discharged home in the 
course of 1 hour. When starting the procedure, we have 
a prepackage set at our disposal which consists of all the 
necessary devices. Performing an analysis of the cost of 
this approach, revealed to be relatively low, thus mak-
ing it more accessible for lthe arger cohort of patients 
relatively low, it more accessible for a large cohort of 
patients suffering from varices. Results obtained from 
12-month follow-up demonstrated the highly efficacious 
nature of the procedure reaching 92%. Although 15 of 
200 patients experienced recanalization, some of them 
did not require reintervention- partial recanalization, 
whereas remaining 10 cases had their vein successfully 
closed with a second procedure. The low number of 
complications and a cosmetic effect widely accepted 
by patients allowed us to add this method to the list of 
minimally-invasive procedures and should be seriously 
considered by medical professionals treating superficial 
vein insufficiencies [14, 19, 20]. 
Conclusions
Based on obtained results we were to summarize 
the following conclusions:
 — high 12-month follow-up effectiveness reaching 
92% of closed/ablated veins;
 — vein diameter is not a limitation for this method;
 — the low rate of serious complications;
 — good cosmetic effect;
 — the method requires further long-term follow-up to 
fully determine the actual effectiveness of the mech-
anochemical technique using Flebogrif®, therefore 
obtained findings should be treated as preliminary.
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